Results meet target and validate method of treatment.
Phase 3 study met target: significantly prolonged survival rates.
Results of trial consistant with previous results. Final data to be released on April 28 (two weeks).
More than 1,000 patients participated.
Great news for PRR's imunotherapy.
dendreon's provenge results meet target
-
- There are more pages in this discussion • 111 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
33.5¢ |
Change
0.025(8.06%) |
Mkt cap ! $486.6M | |||
| Open | High | Low | Value | Volume |
| 32.0¢ | 34.8¢ | 31.3¢ | $1.379M | 4.179M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 170360 | 33.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 34.0¢ | 115131 | 3 |
View Market Depth
| Last trade - 16.10pm 14/08/2024 (20 minute delay) ? |
| IMM (ASX) Chart |